Chronic Aseptic Myometritis: A Mechanistic Framework Linking Sterile Myometrial Inflammation to Uterine Fibroid Initiation and a Roadmap for Primary Prevention.

Saba Haq, Fatimah Hussein, Ola Elamin, Mervat M Omran, Jakub Kociuba, Michal Ciebiera, Mahya Mohammadi, Esra Cetin, Everett Tate, Obianuju Sandra Madueke-Laveaux, Mira Mousa, Mostafa Borahay, Mohamed Ali, Ayman Al-Hendy

Journal: Cells 2026;15(16):

PMID: 42645197

Abstract

Uterine fibroids, the most common tumors in reproductive-age women, remain without a defined precursor tissue state. Unlike cervical dysplasia preceding cervical cancer, or colonic polyps preceding colorectal malignancy, no equivalent "at-risk" tissue marker exists for fibroids, and diagnosis relies on radiological imaging only after tumors are already well-established and often symptomatic including excessive menstrual bleeding, pelvic pain, infertility and obstetric complications. In this narrative review, we propose that a subset of women with unexplained AUB may harbor a chronic, non-infectious inflammatory condition of the myometrium, which we term Chronic Aseptic Myometritis (CAM). We synthesize mechanistic and human tissue evidence suggesting that sterile inflammation driven by damage-associated molecular patterns, NLRP3 inflammasome activation, oxidative DNA damage, and TGF-β-mediated extracellular-matrix remodeling may underlie the transition from normal myometrium (MyoN) to a pre-fibroid, inflamed and stiffened state (MyoF), and may contribute both to abnormal uterine bleeding (AUB) and to fibroid initiation. We propose a preliminary framework for future CAM research, including the identification of candidate biomarker categories and imaging correlates. We also discuss whether early mechanism-based interventions, such as vitamin D and epigallocatechin gallate (EGCG), may offer a potential pathway toward primary prevention. Because the components of this model derive largely from experimental and cross-sectional human studies, CAM is presented as a hypothesis-generating, myometrium-centered framework rather than a validated clinical entity, and prospective validation is required.

Address: Department of Medical Science, Khalifa University, Abu Dhabi 127788, United Arab Emirates.; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.; Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11769, Egypt.; Department of Gynecology, Obstetrics and Gynecological Endocrinology, 00-189 Warsaw, Poland.; Warsaw Institute of Women's Health, 00-189 Warsaw, Poland.; Department of Gynecology, Obstetrics and Gynecological Endocrinology, 00-189 Warsaw, Poland.; Warsaw Institute of Women's Health, 00-189 Warsaw, Poland.; Development and Research Center of Non-Invasive Therapies, Pro-Familia Hospital, 35-302 Rzeszow, Poland.; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.; Hurley Medical Center, Michigan State University, East Lansing, MI 48503, USA.; Department of Public Health and Epidemiology, College of Health and Medical Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates.; Center for Biotechnology, College of Health and Medical Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates.; Department of Gynecology & Obstetrics, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.; Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.; Department of Medical Science, Khalifa University, Abu Dhabi 127788, United Arab Emirates.; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.